Review of NICE Technology Appraisal Guidance No. 32; Multiple sclerosis - interferon beta and glatiramer acetate, No. 127; Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis, and No. 254; Fingolimod for the treatment of relapsing-remitting multiple sclerosis

The Institute was proposing that a combined review of TA32, TA127 and TA254 should be planned into the NICE work programme.

During consultation, the majority of comments received by the Institute agreed with the proposal put forward, but there were concerns that commencing with an early review of the existing guidance would mean that important evidence would not be considered.  Stakeholders proposed that the review of the existing guidance should be scheduled into the work programme at such a time that new expected evidence could be taken into account.  After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with this proposal.

Consequently, a review of TA32, TA127 and TA254 will be planned into the NICE work programme as originally proposed, but this review will not begin until 2015.

July 2013